

(51) International Patent Classification:
C07D 491/00 (2006.01)(21) International Application Number:
PCT/US2009/049318(22) International Filing Date:
30 June 2009 (30.06.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/077,091 30 June 2008 (30.06.2008) US
61/156,426 27 February 2009 (27.02.2009) US
61/180,095 20 May 2009 (20.05.2009) US(71) Applicant (for all designated States except US): **CY-LENE PHARMACEUTICALS, INC.** [US/US]; 5820 Nancy Ridge Drive, Suite 200, San Diego, CA 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HADDACH, Mustapha** [US/US]; 3545 Arnold Avenue, San Diego, CA 92104 (US). **NAGASAWA, Johnny, Yasuo** [JP/US]; 8976 Revelstoke Way, San Diego, CA 92126 (US).(74) Agents: **BELUSKO, Vincent, J.** et al.; Morrison & Foerster LLP, 12531 High Bluff Drive, Suite 100, San Diego, CA 92130-2040 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: OXINDOLE COMPOUNDS




FIG. 2

(57) Abstract: The invention provides compounds that inhibit PIM kinases and Flt3 kinase, and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation.



Published:

— *with international search report (Art. 21(3))*